logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.
    • Compare Medications
    olumiant (baricitinib)More info
    xeljanz/xeljanz xr (tofacitinib)More info
    efficacy
    safety
    indications
    Coverage
    dosing
    pharmacology
    Savings
    efficacy
    ACR20 Response at Week 12
    cDMARD-IR: 66%; TNFi-IR: 49%
    cDMARD-IR: 55%; TNFi-IR: 41%
    ACR50 Response at Week 12
    cDMARD-IR: 34%; TNFi-IR: 20%
    cDMARD-IR: 29%; TNFi-IR: 26%
    ACR20 Response at Week 24
    cDMARD-IR: 61%; TNFi-IR: 45%
    cDMARD-IR: 50%; TNFi-IR: 51%
    ACR50 Response at Week 24
    cDMARD-IR: 41%; TNFi-IR: 23%
    cDMARD-IR: 32%; TNFi-IR: 37%
    Review efficacy data to choose the clinically appropriate treatment for your patient
    safety
    Black Box Warning
    Yes
    Yes
    Contraindications
    None
    None
    Most Common Adverse Reactions
    In RA (incidence ≥1%): upper respiratory tract infections, nausea, herpes simplex, herpes zoster
    In RA within first 3 months of placebo-controlled trials (≥2% with XELJANZ ± DMARDs): upper respiratory tract infection, nasopharyngitis, diarrhea, headache
    indications
    Adult Rheumatoid Arthritis (moderately to severely active RA with inadequate response to one or more TNF blockers)
    Yes
    Yes
    COVID-19 (hospitalized, requiring oxygen)
    Yes
    No
    Alopecia Areata
    Yes
    No
    Psoriatic Arthritis
    No
    Yes
    Ulcerative Colitis
    No
    Yes
    Ankylosing Spondylitis
    No
    Yes
    Juvenile Idiopathic Arthritis
    No
    Yes (patients 2+ years)
    Coverage
    Add insurance carrier above to get more details about the coverage for each medication
    dosing
    Standard Dosing
    2 mg once daily orally, with or without food
    5 mg twice daily or XELJANZ XR 11 mg once daily
    Mild Renal Impairment Dosing
    2 mg once daily
    No dose adjustment needed
    Moderate Renal Impairment Dosing
    1 mg once daily
    5 mg once daily
    Severe Renal Impairment Dosing
    Not recommended
    5 mg once daily
    Moderate Hepatic Impairment Dosing
    No dose adjustment needed
    5 mg once daily
    pharmacology
    Mechanism of Action
    JAK1/2 inhibitor with some TYK2 activity
    JAK inhibitor with preferential inhibition of JAK1/JAK3 and JAK1/JAK2 combinations
    Half-life
    ~12-16 hours in RA and alopecia areata patients
    About 3 hours (immediate-release), 6-8 hours (extended-release)
    Time to Peak
    1 hour
    0.5-1 hours (immediate-release), 4 hours (extended-release)
    Bioavailability
    ~80%
    74%
    Savings
    Savings
    Coverage Not Required
    $25Olumiant (baricitinib)
    Learn more about this program
    Get savings card
    View All Programs
    No data available
    Alternative Drug Suggestions